The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
Open accessAbstract
BACKGROUND: In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk. METHODS: We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. RESULTS: A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P=0.79 by the log-rank test). CONCLUSIONS: Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Post hoc and prespecified subgroup analyses and meta-analyses of 5 major fibrate trialsdHelsinki Heart Study, Veterans Affairs HDL Intervention Trial, Bezafibrate Infarction Project, FIELD, and ACCORD-Lipiddhave shown a CV benefit in persons with moderate dyslipidemia (triglycerides >200 mg/dL and HDL-C <40 mg/dL, either isolated or together) but not in persons without dyslipidemia.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [378]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [123]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, a previous trial of niacin 4 and two previous trials of fenofibrate 5,6 showed no significant decrease in cardiovascular risk, although triglyceride levels were lowered by 26%, 29%, and 26%, respectively.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the exception of the FIELD trial, all these trials involved patients who were receiving statins.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benefits in outcome studies appear limited to subgroups with high TG and low HDL-C, highlighting the complexity of translating TG reduction into ASCVD risk reduction [61, 74–77].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, traditional TG-lowering agents, such as fibrates and niacin, have demonstrated inconsistent CVD benefits in randomized trials, even when lipid changes were robust.”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two large randomized controlled trials (RCTs) evaluating the efficacy of extended-release niacin vs placebo on background statin therapy in individuals with established ASCVD did not demonstrate a reduction in vascular events”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the recently concluded AIM-HIGH study did not report any further benefits with regard to cardiovascular events when niacin was added to a statin in patients with median triglyceride level of about 160 mg/dl in the mild hypertriglyceridemia range and average LDL cholesterol levels below 80 mg/dl (177).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [177]
The cited source says what the claim attributes to it.
In the citing paper
“whether lowering these levels would also lower the incidence of cardiovascular events remains controversial.”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“These neutral findings with pemafibrate are consistent with those from the contemporary Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH) trial 2 of high-dose n-3 fatty acids, the previous Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (160)”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [160]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, there was a possible increased risk of ischemic stroke in the AIM-HIGH trial (154) and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (155).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [154]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Studies, such as the Copenhagen City Heart Study involving 9330 individuals, indicate a progressive rise in myocardial infarction risk over a decade with increasing Lp(a) levels [13].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredIn the citing paper
“The observed annualized primary endpoint event rate for placebo patients in REDUCE-IT was 5.74%, which is consistent with historical cardiovascular outcome studies, including those published since the design of REDUCE-IT, with comparable patient populations and expanded or hard major adverse cardiovascular events (MACE) (4,8,9,30-44).”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [30]
In the citing paper
“Combinations of statins with fibrates, niacin, or fish oil have thus far generally failed to demonstrate cardiovascular benefits beyond that achieved with statins alone.128–132”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [129]
In the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“In the Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (dal-OUTCOMES) trial, treatment with the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib increased HDL-C without any effect on LDL-C or ApoB, but did not reduce the risk of major CV events [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“The CETP inhibitors dalcetrapib (in > 30 000 patients with recent ACS [65]) and evacetrapib (in > 12 000 high-risk patients [63]) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors [65].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [65]
In the citing paper
“Niacin also lowers LDL-C levels by 15–20%,49 but recent large randomized trials showed a significant excess of adverse effects and no significant CVD benefit when added to background statin treatment; therefore, niacin derivatives are no longer available for prescription in Europe.50,51”
In the citing paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Twolarge randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Two large randomized clinical trials [the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE)] using, respectively, extended release (ER) nicotinic acid vs. placebo in addition to simvastatin, and ER nicotinic acid/l”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“After two large studies with nicotinic acid, one with extended-release niacin 251 and one with niacin plus laropiprant, 252 showed no beneficial effect, but rather an increased frequency of serious adverse effects, no medication containing nicotinic acid is currently approved in Europe.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Modest regression of carotid atherosclerosis with niacin in most (but not all) imaging studies was not supported by clinical benefit in the AIM-HIGH and HPS2-THRIVE trials.251,252”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“Niacin did not reduce stroke over longterm follow-up in patients with CVD in the AIM-HIGH and HPS2-THRIVE trials.251,252”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [251]
In the citing paper
“With respect to primary endpoints of these studies, although the effectiveness of fenofibrate was not demonstrated, a meta-analysis in primary prevention using fibrates revealed that deaths from cerebrovascular and cardiovascular diseases, non-fatal myocardial infarction, and non-fatal stroke significantly decreased by 16%651).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [651]
In the citing paper
“Combination therapy using ethyl icosapentate (EPA) preparation or fibrate with statin is effective in suppressing ASCVD incidence. (Evidence level 2, recommendation level B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [696]
In the citing paper
“In a sub-analysis of JELIS study696) which enrolled subjects with hypercholesterolemia, it was shown that EPA administration added-on to statins prevented coronary event incidence for patients in primary prevention whose TG and HDL-C levels were ≥ 151 mg/dL and < 40 mg/dL, respectively.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [696]
In the citing paper
“Meta-analyses of studies with niacin (mostly without simultaneous administration of statins) indicate a decrease in cardiovascular events [92–94].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [92]
In the citing paper
“outcome trials that have targeted HDL-C pharmacologically and have included patients with low HDL-C at baseline, have not demonstrated reduced CVD risk despite appreciable increases in HDL-C.5-10”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [7]
In the citing paper
“In contrast, recent studies have failed to demonstrate that high HDL-C acquired naturally or pharmacologically, is associated with reduced CVD risk.5-11,18”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease
Khot, U. N. (2003) · JAMA · doi:10.1001/jama.290.7.898 · Cited by 1,494
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 888
Flagged first, then by citations
Research works printed but not linked: 1
- Castelli WP, 1988, Can J Cardiol, 4, 5A
Cited by
Sorted by citations
Items 401–500 of 1,019
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
White, C. R., Garber, D. W., & Anantharamaiah, G. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r051367 · Cited by 91
Tumurkhuu, G., Dagvadorj, J., Porritt, R. A., Crother, T. R., Shimada, K., Tarling, E. J., Erbay, E., Arditi, M., & Chen, S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.027 · Cited by 89
PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86
Generating comparative evidence on new drugs and devices after approval
Cipriani, A., Ioannidis, J. P. A., Rothwell, P. M., Glasziou, P., Li, T., Hernandez, A. F., Tomlinson, A., Simes, R. J., & Naci, H. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33177-0 · Cited by 89
HDL and type 2 diabetes: the chicken or the egg?
Xepapadaki, E., Nikdima, I., Sagiadinou, E. C., Zvintzou, E., & Kypreos, K. E. (2021) · Diabetologia · doi:10.1007/s00125-021-05509-0 · Cited by 89
Is a High HDL-Cholesterol Level Always Beneficial?
Franczyk, B., Rysz, J., Ławiński, J., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2021) · Biomedicines · doi:10.3390/biomedicines9091083 · Cited by 94
Metabolic Syndrome, ESRD, and Death in CKD
Navaneethan, S. D., Schold, J. D., Kirwan, J. P., Arrigain, S., Jolly, S. E., Poggio, E. D., Beddhu, S., & Nally, J. V. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09870912 · Cited by 86
High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity
Rohatgi, A. K. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.05.004 · Cited by 87
Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation
Offermanns, S., & Schwaninger, M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.002 · Cited by 91
The Relationships Between Cardiovascular Disease and Diabetes
Kovacic, J. C., Castellano, J. M., Farkouh, M. E., & Fuster, V. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.007 · Cited by 89
Joo, H. J., Cho, S.-A., Hong, S. J., Hur, S., Bae, J., Choi, D., Ahn, Y., Park, J., Choi, R. K., Choi, D., et al. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0374-5 · Cited by 85
Dyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 88
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options
Likozar, A. R., Zavrtanik, M., & Šebeštjen, M. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1775287 · Cited by 91
Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study
Lenglet, A., Liabeuf, S., Esper, N. E., Brisset, S., Mansour, J., Lemaire‐Hurtel, A., Mary, A., Brazier, M., Kamel, S., Mentaverri, R., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw042 · Cited by 85
Handelsman, Y., & Lepor, N. E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008953 · Cited by 88
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Statin-associated muscle symptoms—Managing the highly intolerant
Backes, J. M., Ruisinger, J. F., Gibson, C., & Moriarty, P. M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.006 · Cited by 88
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 87
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 86
The Treatment of Disorders of Lipid Metabolism
Parhofer, K. G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0261 · Cited by 86
Dyslipidemia and Cardiovascular Disease in Women
Cífková, R., & Krajčoviechová, A. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0609-5 · Cited by 86
Qiu, C., Zhao, X., Zhou, Q., & Zhang, Z. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0604-5 · Cited by 89
Mason, R. P., Dawoud, H., Jacob, R. F., Sherratt, S. C. R., & Maliñski, T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.118 · Cited by 87
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
Matsuura, Y., Kanter, J. E., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311999 · Cited by 88
The role of adiponectin in cholesterol efflux and HDL biogenesis and metabolism
Hafiane, A., Gasbarrino, K., & Daskalopoulou, S. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153953 · Cited by 84
Rahman, M. S., & Woollard, K. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57613-8_7 · Cited by 87
Atherosclerosis in Systemic Lupus Erythematosus
Stojan, G., & Petri, M. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31829dd857 · Cited by 86
HDL and cholesterol: life after the divorce?
Vickers, K. C., & Remaley, A. T. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r035964 · Cited by 87
Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials
Goldie, C., Taylor, A. J., Nguyen, P., McCoy, C. W., Zhao, X.-Q., & Preiss, D. (2015) · Heart · doi:10.1136/heartjnl-2015-308055 · Cited by 84
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease
Rahman, M. S., Murphy, A. J., & Woollard, K. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.34 · Cited by 86
Dyslipidemia and its therapeutic challenges in renal transplantation
Riella, L. V., Gabardi, S., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04084.x · Cited by 82
Ahmed, H. M., Miller, M. J., Nasir, K., McEvoy, J. W., Herrington, D. M., Blumenthal, R. S., & Blaha, M. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv305 · Cited by 83
PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes
Hess, C. N., Wang, C. C. L., & Hiatt, W. R. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042716-091351 · Cited by 87
Singh, K., Chandra, A., Sperry, T., Joshi, P. H., Khera, A., Virani, S. S., Ballantyne, C. M., Otvos, J. D., Dullaart, R. P. F., Gruppen, E. G., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045713 · Cited by 83
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
Kim, K., Ginsberg, H. N., & Choi, S. H. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0198 · Cited by 88
Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression
Kaur, N., Pandey, A. K., Negi, H., Shafiq, N., Reddy, S., Kaur, H., Chadha, N., & Malhotra, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094585 · Cited by 83
Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD
Fuchs, C. D., Claudel, T., & Trauner, M. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.08.001 · Cited by 85
Wissing, K. M., & Pipeleers, L. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.004 · Cited by 83
Sahebkar, A., Beccuti, G., Simental‐Mendía, L. E., Nobili, V., & Bo, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.008 · Cited by 82
Triglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 87
Consensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 86
Mendelian randomization studies
Ference, B. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000247 · Cited by 84
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial
Anderson, T. J., Boden, W. E., Desvigne-Nickens, P. M., Fleg, J. L., Kashyap, M. L., McBride, R., & Probstfield, J. L. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1311039 · Cited by 81
Akioyamen, L. E., Genest, J. J., Chu, A., Inibhunu, H., Ko, D. T., & Tu, J. V. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.10.012 · Cited by 86
Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management
Najam, O., & Ray, K. K. (2015) · Cardiology and Therapy · doi:10.1007/s40119-015-0037-z · Cited by 84
Kallend, D. G., Reijers, J. A. A., Bellibas, S. E., Bobillier, A., Kempen, H. J. M., Burggraaf, J. L. I., Moerland, M., & Wijngaard, P. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv041 · Cited by 80
WEINTRAUB, H. S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.041 · Cited by 82
HDL, Atherosclerosis, and Emerging Therapies
Hafiane, A., & Genest, J. J. (2013) · Cholesterol · doi:10.1155/2013/891403 · Cited by 82
Huang, C., Lin, F., Shih, C., Au, H., Chang, Y., Nakagami, H., Morishita, R., Chang, N., Shyu, K., & Chen, J. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.248617 · Cited by 80
Ganda, A., Magnusson, M., Yvan‐Charvet, L., Hedblad, B., Engström, G., Ai, D., Wang, T. J., Gerszten, R. E., Melander, O., & Tall, A. R. (2013) · Circulation · doi:10.1161/circulationaha.112.000682 · Cited by 80
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 86
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes‐Soffer, G., Yeang, C., Michos, E. D., Boatwright, W., & Ballantyne, C. M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100651 · Cited by 84
Liu, M., Seo, J., Allegood, J. C., Bi, X., Zhu, X., Boudyguina, E. Y., Gebre, A. K., Avni, D., Shah, D., Sorci‐Thomas, M. G., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.499913 · Cited by 82
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Joshi, S. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1009894 · Cited by 81
Mutharasan, R. K., Thaxton, C. S., Berry, J. D., Daviglus, M. L., Yuan, C., Sun, J., Ayers, C. R., Lloyd‐Jones, D. M., & Wilkins, J. T. (2017) · Journal of Lipid Research · doi:10.1194/jlr.p069039 · Cited by 85
The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
Wong, N. K. P., Nicholls, S. J., Tan, J. T. M., & Bursill, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061680 · Cited by 77
A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels
Carswell, K. A., Belgaumkar, A. P., Amiel, S. A., & Patel, A. G. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1829-x · Cited by 78
High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm
Tuteja, S., & Rader, D. J. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.79 · Cited by 77
Angeloni, E., Paneni, F., Landmesser, U., Benedetto, U., Melina, G., Lüscher, T. F., Volpe, M., Sinatra, R., & Cosentino, F. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht163 · Cited by 79
Recomendaciones preventivas cardiovasculares
Galán, Á. M. M., Cuixart, C. B., Álvarez, F. V., Pérez, J. N., Lobos-Bejarano, J. M., Sánchez-Pinilla, R. O., Rioboó, E. M., Banegas, J. R. B., Orozco‐Beltrán, D., & Gil-Guillén, V. F. (2012) · Atención Primaria · doi:10.1016/s0212-6567(12)70010-0 · Cited by 78
Mason, R. P., & Jacob, R. F. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.016 · Cited by 78
HDL-cholesterol and cardiovascular disease: rethinking our approach
Siddiqi, H. K., Kiss, D., & Rader, D. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000211 · Cited by 77
When should we measure lipoprotein (a)?
Kostner, K., März, W., & Kostner, G. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht053 · Cited by 77
Fu, L., Tai, S., Sun, J., Zhang, N., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S. (2022) · Diabetes Care · doi:10.2337/dc21-2511 · Cited by 78
HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients
Annema, W., Dikkers, A., de Boer, J. F., Dullaart, R. P. F., Sanders, J., Bakker, S. J. L., & Tietge, U. J. F. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014090857 · Cited by 79
GPR109A and Vascular Inflammation
Chai, J. T., Digby, J. E., & Choudhury, R. P. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0325-9 · Cited by 78
MicroRNA expression signature in human abdominal aortic aneurysms
Pahl, M. C., Derr, K., Gäbel, G., Hinterseher, I., Elmore, J. R., Schworer, C. M., Peeler, T. C., Franklin, D. P., Gray, J. L., Carey, D. J., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-25 · Cited by 77
McGarrah, R. W., Craig, D. M., Haynes, C. S., Dowdy, Z. E., Shah, S. H., & Kraus, W. E. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.012 · Cited by 77
Pharmacological Intervention to Modulate HDL: What Do We Target?
Woudberg, N. J., Pedretti, S., Lecour, S., Schulz, R., Vuilleumier, N., James, R. W., & Frias, M. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00989 · Cited by 80
Beyond Coronary Calcification, Family History, and C-Reactive Protein
Mody, P. S., Joshi, P. H., Khera, A., Ayers, C. R., & Rohatgi, A. K. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.538 · Cited by 76
Cholesterol efflux capacity: An introduction for clinicians
Anastasius, M. O., Kockx, M., Jessup, W., SULLIVAN, D. R., Rye, K., & Kritharides, L. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.005 · Cited by 78
Cholesterol levels and long-term rates of community-acquired sepsis
Guirgis, F. W., Donnelly, J. P., Dodani, S., Howard, G., Safford, M. M., Levitan, E. B., & Wang, H. E. (2016) · Critical Care · doi:10.1186/s13054-016-1579-8 · Cited by 76
Salahuddin, T., Natarajan, B., Playford, M. P., Joshi, A. A., Teague, H., Masmoudi, Y., Selwaness, M., Chen, M. Y., Bluemke, D. A., & Mehta, N. N. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv339 · Cited by 77
Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study
Langsted, A., Nordestgaard, B. G., & Kamstrup, P. R. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1085 · Cited by 72
Khera, A. V., Patel, P. J., Reilly, M. P., & Rader, D. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.025 · Cited by 74
Niacin: an old lipid drug in a new NAD+ dress
Romani, M., Hofer, D., Katsyuba, E., & Auwerx, J. H. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s092007 · Cited by 72
Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients
Maningat, P. D., & Breslow, J. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1112023 · Cited by 74
Mendivil, C. O., Furtado, J. D., Morton, A. M., Wang, L., & Sacks, F. M. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306138 · Cited by 76
Diabetes Impairs Cellular Cholesterol Efflux From ABCA1 to Small HDL Particles
He, Y., Ronsein, G. E., Tang, C., Jarvik, G. P., Davidson, W. S., Kothari, V. M., Song, H. D., Segrest, J. P., Bornfeldt, K., & Heinecke, J. W. (2020) · Circulation Research · doi:10.1161/circresaha.120.317178 · Cited by 74
Triglyceride and Triglyceride-Rich Lipoproteins in Atherosclerosis
Zhang, B., Yin, F., Qiao, Y.-N., & Guo, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.909151 · Cited by 83
Patel, S. B., Wyne, K. L., Afreen, S., Belalcazar, L. M., Bird, M. D., Coles, S., Marrs, J. C., Peng, C. C., Pulipati, V. P., Sultan, S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.016 · Cited by 80
Nam, K., Chang, T., Joo, Y. S., Kim, J., Lee, S.-M., Lee, C., Yun, H., Park, J., Yoo, T., Sung, S.-A., et al. (2019) · Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease · doi:10.1161/jaha.118.011162 · Cited by 59
Self-citationGordon, S. M., Deng, J., Tomann, A. B., SHAH, A. S., Lu, L. J., & Davidson, W. S. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.028134 · Cited by 72
New Therapeutic Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 75
Mason, R. P., Sherratt, S. C. R., & Jacob, R. F. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000379 · Cited by 72
Statin Intolerance: A Literature Review and Management Strategies
Saxon, D. R., & Eckel, R. H. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.009 · Cited by 75
Brinton, E. A., Ballantyne, C. M., Bays, H. E., Kastelein, J. J., Braeckman, R. A., & Soni, P. N. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-100 · Cited by 70
Huang, L., Fan, B., Ma, A., Shaul, P. W., & Zhu, H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054742 · Cited by 71
Triolo, M., Annema, W., Dullaart, R. P. F., & Tietge, U. J. F. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.35 · Cited by 71
Hendrani, A. D. (2016) · World Journal of Cardiology · doi:10.4330/wjc.v8.i2.201 · Cited by 71
The role of monocytosis and neutrophilia in atherosclerosis
Chistiakov, D. A., Grechko, A. V., Myasoedova, V. A., Melnichenko, A. А., & Orekhov, A. N. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13462 · Cited by 75
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
Epigenetic Signatures and Vascular Risk in Type 2 Diabetes: A Clinical Perspective
Paneni, F., Costantino, S., Volpe, M., Lüscher, T. F., & Cosentino, F. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.003 · Cited by 70
Regression of Atherosclerosis: Insights from Animal and Clinical Studies
Feig, J. E. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2013.12.001 · Cited by 71
Gordon, S. M., & Remaley, A. T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.015 · Cited by 72
Gudzune, K. A., Monroe, A. K., Sharma, R., Ranasinghe, P. D., Chelladurai, Y., & Robinson, K. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2526 · Cited by 73
Niesor, E. J., Schwartz, G. G., Perez, A., Stauffer, A., Durrwell, A., Suchánková, G., Benghozi, R., Abt, M., & Kallend, D. G. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6570-0 · Cited by 70
Gilbert, O. N., Croffoot, J. R., Taylor, A. J., Nash, M. S., Schomer, K. G., & Groah, S. L. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.11.028 · Cited by 69
Metadata
- Authors
- The AIM-HIGH Investigators
- Corresponding author
- The AIM-HIGH Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-15
- Volume
- 365
- Issue
- 24
- Pages
- 2255-2267
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2165605025
- Semantic Scholar
- d76ac03611110eeffa5c3ad8b47d06f372d84eb6
- Cited by
- 2,911
- References
- 19
- Citations by year
- 2026: 79 · 2025: 90 · 2024: 138 · 2023: 133 · 2022: 138 · 2021: 165 · 2020: 146 · 2019: 181 · 2018: 208 · 2017: 203 · 2016: 264 · 2015: 302 · 2014: 316 · 2013: 333 · 2012: 192
- FWCI
- 280.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Pfizer
- Sanofi
- Genentech
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- nicotinic acid, simvastatin, HDL cholesterol, low HDL cholesterol, residual cardiovascular risk, atherosclerotic cardiovascular disease, extended-release niacin, ezetimibe, LDL cholesterol, triglycerides, major adverse cardiovascular events, cardiovascular risk reduction, statin therapy, coronary artery disease, myocardial infarction, ischemic stroke, acute coronary syndrome, revascularization
- MeSH terms
- Aged, Hypolipidemic Agents, Cardiovascular Diseases, Brain Ischemia, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Muscular Diseases, Niacin, Triglycerides, Proportional Hazards Models, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Atherosclerosis, Kaplan-Meier Estimate, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
